FDA Approves Leucovorin for Rare Brain Condition While Distancing from Autism Treatment Claims
The Food and Drug Administration has granted approval for a generic medication to treat an extremely rare neurological disorder, while simultaneously stepping away from previous assertions by Trump administration officials regarding the drug’s potential benefits for autism patients.
On Tuesday, federal regulators authorized leucovorin for treating individuals with a genetic condition that prevents adequate folate delivery to the brain. This vitamin B deficiency disorder affects an estimated fewer than one person per million in the United States, according to FDA calculations.
The approval represents a significant retreat from claims made during a September White House press briefing, where former President Trump and FDA Commissioner Marty Makary suggested the medication was being evaluated for autism treatment, particularly for patients experiencing folate deficiency in brain tissue.
During that September event, Makary indicated that the condition might affect a substantial portion of children diagnosed with autism spectrum disorder, potentially reaching 20 to 50 percent of cases.
The announcement followed commitments from Health Secretary Robert F. Kennedy Jr. to identify autism’s underlying causes by September’s end.
FDA leadership clarified to media representatives on Monday that their evaluation process had been refined to concentrate on the most compelling scientific evidence, which exclusively supported the medication’s application for patients with the specific genetic mutation affecting brain folate levels.
Regulatory officials also highlighted that research supporting leucovorin’s autism applications had been withdrawn from publication earlier in the year due to validity concerns.
Leucovorin functions as an artificial form of folate, a nutrient crucial for healthy fetal development and recommended for women planning pregnancy. The drug currently holds FDA authorization for mitigating chemotherapy side effects and managing a specific blood condition.
Individuals with the newly approved indication typically experience motor dysfunction, seizure activity, and various neurological symptoms that may mirror certain autism characteristics.
However, established medical organizations maintain that evidence supporting leucovorin’s effectiveness in autism treatment remains inconclusive.
The American Academy of Pediatrics does not endorse routine leucovorin administration for children with autism, even those diagnosed with cerebral folate deficiency. While some clinical trials suggest possible benefits for this patient subset, the organization notes these findings derive from limited-scale research studies.
Despite ongoing uncertainties, American physicians continue prescribing the medication off-label. Recent data published in The Lancet revealed a 71 percent increase in leucovorin prescriptions for children aged 5-17 during the three months following Trump’s September announcement. Families seeking autism treatment have subsequently reported difficulties obtaining prescriptions at pharmacies.
To address supply shortages, FDA officials announced they are permitting international manufacturers to import the medication. GSK, the original producer, has indicated no plans to resume domestic production.
The initial review process began after Trump administration officials consulted with an Arizona neurologist who prescribes leucovorin for autism patients and operates an online educational platform promoting the experimental treatment approach.
The treatment rationale suggests that certain autism patients produce antibodies that prevent folate from crossing into brain tissue. However, the Autism Science Foundation and other research organizations point out that non-autistic family members frequently possess identical antibodies, indicating these proteins may not contribute to autism development.
While autism lacks a singular causative factor, current scientific consensus identifies genetic predisposition and environmental influences as primary contributing elements to the condition’s emergence.